Searched for
TRICOR
'Saturday Night Live' star Pete Davidson headed to space on Jeff Bezos' Blue Origin craftThe launch is scheduled for March 23 and Davidson will be the third celebrity on the flight.- Alembic Pharma gets USFDA nod for cholesterol lowering drugIn a regulatory filing, Alembic Pharma said "it has received final approval from the US Food and Drug Administration (USFDA) for its abbrev...
- Jack Ma’s Ant Group plans dual IPOs in Shanghai, HKThe parent of China’s largest mobile payment company will pursue a simultaneous dual-listing in Hong Kong and on the Shanghai stock exchang...
- Dr Reddy's launches generic lipid-regulating tablets in USPharma major Dr Reddy's Laboratories on Monday said it has launched generic lipid-regulating tablets in the US market.
- Aurobindo Pharma gets final USFDA nod for cholesterol drug"The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fenofibrate Tablets, 48 m...
- Lupin: US launches, better movement of rupee add valueDrugmaker Lupin’s performance in the quarter to December indicates a better showing by the company in the second half of the current fiscal.
- Lupin's earnings outperform Street expectations, to stay our top pick: Kirit Gogri, Quant Broking"The US business has been a big game changer for Lupin and I am presuming that the US business would have delivered much superior numbers t...
- iBerry launches 'Octa-core' tabletTechnology firm iBerry has launched a Octa-core processor-based tablet, the first in India, and said it is the cheapest in the segment.
- Lupin Q2 net profit seen up 35% at Rs 377 crAccording to analysts, the company’s US business is seen growing around 30 per cent while domestic business may see a growth of 10 – 12 per...
- Credit Suisse downgrades Lupin, cites unfavourable risk rewardCredit Suisse has downgraded Lupin from ‘outperform’ to ‘neutral’ rating as risk reward appears unfavourable, Asia Pacific-focused broker s...
- Lupin falls nearly 5% on Mylan drug launch, Credit Suisse downgradeCredit Suisse downgraded Lupin from ‘outperform’ to ‘neutral’ rating and upped the price target from Rs 710 earlier to Rs 755.
- Lupin remains top pick of brokerages in pharma spaceThe stock has extended overnight gains after the company reported a Q4 net profit of Rs 408 crore, up 161 pc YoY.
- US, Indian markets main drivers of growth in Q4: Nilesh Gupta, LupinIn the US, there are some products like Ziprasidone, Fortamet and products that we introduced like Tricor have been doing very well for the...
- Lupin launches generic Tricor in the USLupin has launched generic version of Tricor in the US market after getting approval from the US Food and Drug Administration.
- Lupin to gain from Tricor launch in US, says NomuraNomura analysts said that Lupin's launch of generic Tricor in the US is positive for the company and could emerge with the largest market s...
- Consumer staples no more defensive: CLSACLSA prefers pharmas to consumer staples as a defensive bet, and replaced Tata Motors with Lupin in its top 5 picks.
- Lupin gets USFDA nod for generic cholesterol drugThe US health regulator has granted approval to Lupin to market generic Fenofibrate Tablets, a cholesterol lowering drug, in the American m...
- Hedged all forex exposure for short term: S Ramesh, CFO, LupinIn an interview with ET Now, S Ramesh, CFO, Lupin, talks about pharma and company's strategies.
- Abbott, Ranbaxy settle patent suitThe financial upside for Ranbaxy will depend on several factors since there are 3 other drugmakers wanting to launch their versions of the ...
- Abbott buys Solvay drugs unit for $6.6 billionAbbott Laboratories said it would buy the drugs unit of Solvay in a e4.5 billion ($6.6 billion) deal giving Abbott full control of its Belg...
Load More
